Among noncritically ill patients with COVID-19 infection, therapeutic anticoagulation with heparin improved the proportion of patients who survived without need for organ support.

Therapeutic anticoagulation was associated with a 98.6% probability of superiority compared with usual care.

Major bleeding was increased in the therapeutic anticoagulation group.

These results contrast to therapeutic anticoagulation in COVID-19 patients with critical illness.

The primary outcome, proportion of patients who survived until hospital discharge without need for organ support, was 80.2% in the therapeutic anticoagulation group compared with 76.4% in the usual care group (probability of superiority = 98.6%).

Benefit was observed regardless of the baseline D-dimer level.

Read More